.png){kind=icon}
.png){kind=icon}
Return
From PET to targeted radionuclide therapy in the Brain: The emerging role of radiometal-based platforms
.png){kind=icon}
PRE
AI
J
DOI：10.1016/j.jinorgbio.2026.113397.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Radiometal tracers enable positron emission tomography (PET) diagnosis and targeted radionuclide therapy in brain. • Chelator–linker–targeting vector design is critical for stability, selectivity, and pharmacokinetics. • Key hurdles: Blood brain barrier (BBB) limits delivery; heterogeneous targets; off-target uptake/toxicity. • Advances: new chelators, antigen targets, and blood brain barrier (BBB)-bypass delivery strategies.
Journal
IF:
3.2
Papers:
7.1K
Citations:
1.2W
Organization
No organization information available
Cited Papers